Overview
Pharmaceutical

MIZUHO MEDY CO.,LTD.

Mizuho Medy is a Japanese in vitro diagnostics (IVD) company specializing in the development, manufacturing, and sale of rapid immunochromatographic diagnostic kits and genetic testing systems for infectious diseases. Its flagship 'Quick Chaser' product series covers a broad range of pathogens including influenza, SARS-CoV-2, adenovirus, RSV, H. pylori, and Mycoplasma, targeting hospitals, clinics, and point-of-care testing (POCT) settings. The company also offers OTC diagnostic products such as pregnancy and ovulation tests, as well as agricultural virus detection reagents, and operates a proprietary fully integrated R&D, manufacturing, and sales model underpinned by ISO 13485 quality management.

Market Cap
¥32.8B
US$209M
EV
¥19.7B
US$126M
Stock¥1,720▲+0.06%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
4.4
x
LTM EV/EBIT
4.7
x
LTM PER
10.2
x
LTM PBR
1.8
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-15.3%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
32.8BUS$209MMarket Cap0.00BUS$0.00M+ Debt13.1BUS$83.3M− Cash0.00BUS$0.02M− Inv. Sec.19.7BUS$126MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
13.1US$83.8M'21/1217.6US$112M'22/1211.0US$70.1M'23/1211.4US$72.9M'24/1211.3US$71.8M'25/12
EBITDA 5Y (¥B)
6.87US$43.8M'21/1211.3US$72.0M'22/125.35US$34.1M'23/125.15US$32.8M'24/124.91US$31.3M'25/12
Net Income 5Y (¥B)
4.82US$30.7M'21/127.84US$50.0M'22/123.77US$24.1M'23/123.77US$24.1M'24/123.43US$21.8M'25/12
Capital Structure
100%
EquityD/E 0.00xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
4.33US$27.6M'21/128.71US$55.5M'22/1210.1US$64.7M'23/1211.3US$71.8M'24/1210.8US$69.1M'25/12
Shareholders
Top 10 hold 32.3%
1
Fumishige KARAKAWA
20.54%
2
The Nishi-Nippon City Bank, Ltd.
2.09%
3
Mitsubishi UFJ eSmart Securities Co., Ltd.
2.00%
4
MIZUHO MEDY CO.,LTD. Employee Stock Ownership Association
1.96%
5
Junichi MURATA
1.09%
6
Noriyasu KARAKAWA
1.04%
7
BNYM SA/NV FOR BNYM FOR BNY GCM CLIENT ACCOUNTS M LSCB RD (Standing Proxy: MUFG Bank, Ltd.)
1.04%
8
Morgan Stanley MUFG Securities Co., Ltd.
0.98%
9
Manabu OKUMURA
0.85%
10
Taiichiro KARAKAWA
0.73%
Management
10 officers
Fumishige KARAKAWA
Representative Director, Chairman and President
Apr 1968 Joined Otsuka Pharmaceutical Co., Ltd. Jul 1970 Joined Kokusai Shiyaku Co., Ltd. (now Sysmex International Reagents Co., Ltd.) Nov 1977 Founded the Company; Representative Director, President Mar 2016 Representative Director, Chairman and President of the Company (current)
1945-03-12
Kazuhiro ICHIMARU
Director; General Manager, Intellectual Property Department; in charge of Manufacturing Department, Quality Assurance Department and Safety Management Office
Apr 1983 Joined Toho Rayon Co., Ltd. (now Teijin Limited) Nov 1986 Joined the Company Apr 2008 General Manager, Intellectual Property Department Apr 2010 Executive Officer, General Manager, Intellectual Property Department Mar 2011 Director; General Manager, Intellectual Property Department; in charge of Manufacturing Department, Quality Assurance Department and Safety Management Office (current)
1960-10-29
Kenji NARAHARA
Director; General Manager, Development Department; in charge of Development Planning Department
Apr 1986 Joined the Company May 2004 General Manager, Development Department Apr 2008 Executive Officer, General Manager, Development Department Mar 2013 Director, General Manager, Development Department Mar 2025 Director; General Manager, Development Department; in charge of Development Planning Department (current)
1963-11-13
Toshio KAMBARA
Director; General Manager, Sales Headquarters; Head, Overseas Business Division
Apr 1986 Joined Kato Spring Manufacturing Co., Ltd. (now Advanex Inc.) Oct 1994 Joined the Company Apr 2010 Deputy General Manager, East Japan Sales Department May 2013 General Manager, East Japan Sales Department Mar 2015 Director; General Manager, Sales Headquarters; Head, Overseas Business Division (current)
1964-03-11
Nobuhiro UTO
Director; General Manager, General Affairs Department; in charge of Accounting Department
Apr 1984 Joined Fukuoka Mutual Bank, Ltd. (now The Nishi-Nippon City Bank, Ltd.) May 1993 Joined the Company Sep 2015 General Manager, General Affairs Department May 2016 Executive Officer, General Manager, General Affairs Department Mar 2025 Director; General Manager, General Affairs Department; in charge of Accounting Department (current)
1961-03-01
Masaru SASAKI
Director
Apr 1968 Joined Nishi-Nippon Mutual Bank, Ltd. (now The Nishi-Nippon City Bank, Ltd.) Jun 1995 Director of the same bank Jun 2000 Managing Director of the same bank Jun 2002 Senior Managing Director of the same bank Oct 2004 Senior Managing Director, The Nishi-Nippon City Bank, Ltd. Jun 2006 Director and Deputy President, The Nishi-Nippon City Bank, Ltd. Jun 2010 Representative Director, President, FM Fukuoka Inc. Jun 2010 Director, Japan FM Network Co., Ltd. Mar 2015 Director of the Company (current) Jun 2018 Senior Advisor, FM Fukuoka Inc. Aug 2023 Audit and Supervisory Committee Member, Nyosui Audit Corporation (current)
1945-04-20
Shinichi AKIYAMA
Director
Apr 1980 Associate Professor, Department of Biochemistry, Oita Medical University (now Oita University Faculty of Medicine) Apr 1986 Professor and Director, Division of Cancer Chemotherapy, Institute for Tumor Research, Kagoshima University Apr 2003 Professor, Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University; Chair, Advanced Therapeutic Sciences Apr 2010 Professor Emeritus, Kagoshima University; Specially Appointed Professor, Department of Medical Oncology, Institute of Health Biosciences, The University of Tokushima Apr 2012 Visiting Professor, The University of Tokushima; Physician, Takeda Hospital, Keitenkai Medical Corporation Oct 2013 Physician, Kashiigaoka Rehabilitation Hospital, Ikeikai Foundation Feb 2014 Deputy Director, Kashiigaoka Rehabilitation Hospital Mar 2017 Director of the Company (current) Jun 2017 Deputy Director, Yachiyo Rehabilitation Hospital, Kyoju-no-Kai Apr 2022 Director, Department of Convalescent Rehabilitation, Fukuoka Seishukai Hospital, Seishukai Medical Corporation
1945-03-31
Hirotaka KAWASAKI
Full-time Audit & Supervisory Board Member
Apr 1986 Joined the Company May 2015 Deputy General Manager, Sales Planning Department May 2016 General Manager, Sales Planning Department Mar 2019 Full-time Audit & Supervisory Board Member of the Company (current)
1959-01-13
Nobuhiko SHIGEMI
Audit & Supervisory Board Member
Apr 1993 Joined Tohmatsu Audit Corporation (now Deloitte Touche Tohmatsu LLC) Jul 2010 Opened Shigemi Accounting Office Mar 2011 Audit & Supervisory Board Member of the Company (current) Apr 2013 Established Shigemi Accounting Tax Corporation (now Tsuji & Shigemi Tax Corporation); Representative Partner (current) May 2019 Representative Director, President, Sunlight Consulting Co., Ltd. (current) Mar 2024 Audit & Supervisory Board Member, Pacific League Marketing Corporation (current)
1970-10-18
Takayoshi HASHIMOTO
Audit & Supervisory Board Member
Apr 1979 Joined Fukuoka Pharmaceutical Co., Ltd. (now Shoyaku Co., Ltd.) Nov 2001 Joined Kenko Club Co., Ltd. Dec 2004 Representative Director, Kenko Club Co., Ltd. (current) Apr 2005 Director, Utsunomiya Hospital operated by Shiseido-do Medical Corporation Mar 2015 Audit & Supervisory Board Member of the Company (current)
1956-08-03
Large Shareholding Reports
No filings
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-12
Q2 Earnings Flash
FY ending Dec 2026
EDINET
2026-08-12
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-05-13
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-03-26
Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-11-07
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-08-08
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-05-09
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-31
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-08-09
Semi-Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-05-10
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-29
Annual Securities Report
Period: Jan 2023 – Dec 2023
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-05-12
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-03-30
Annual Securities Report
Period: Jan 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-08-10
Quarterly Securities Report
EDINET
2022-05-09
Quarterly Securities Report
EDINET
2022-03-31
Annual Securities Report
EDINET
2021-11-08
Quarterly Securities Report
EDINET
2021-08-10
Quarterly Securities Report
EDINET
2021-05-10
Quarterly Securities Report
EDINET
2021-03-29
Annual Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →